Clinical Trial Update: Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating histidine oral supplementation for Alzheimer's disease has been withdrawn; no results are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Histidine (histidine)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Alzheimer Disease | Phase 4 | Status: WITHDRAWN